INZY News and Press, Inozyme Pharma Inc. From 04/01/21

BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of t...

Inozyme Pharma (INZY): FY GAAP EPS of -$5.11.Cash, cash equivalents, and investments of $159.9MPress Release For further details see: Inozyme Pharma reports FY results

– Received Orphan Drug Designation by the U.S. Food and Drug Administration for INZ-701 for treatment of ABCC6 deficiency – – Expect to initiate Phase 1/2 trials of INZ-701 for ENPP1 deficiency in the first half of the year and ABCC6 deficiency by mid-2021 &...

BOSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today that ENPP1 deficiency will be featured on The Balancing Act ® as p...

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today announ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The Q4 earnings season cranks up with Procter & Gamble (NYSE:PG), Netflix (NASDAQ:NFLX) and Intel (NASDAQ:INTC) some...

Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China's leading e-cigarette brand RLX Technology plans to raise $1.0 billion at a $14.0 billion market cap. Street research is expected for Inhibikase Therape...

Both the FDA and Medicines & Healthcare Products Regulatory Agency in the U.K, have signed off Inozyme Pharma's ([[INZY]] +11.9%) Phase 1/2 trial evaluating INZ-701 in adults with ENPP1 deficiency, a genetic disorder caused by mutations in the ENPP1 gene...

– U.S. Food and Drug Administration cleared Investigational New Drug Application – – United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application – – Program addressing rare mineralization dis...

The following slide deck was published by Inozyme Pharma, Inc. in conjunction with this event. For further details see: Inozyme Pharma (INZY) Investor Presentation - Slideshow